Market Cap 829.54M
Revenue (ttm) 258.00M
Net Income (ttm) -283.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -109.69%
Debt to Equity Ratio 0.10
Volume 2,072,875
Avg Vol 1,040,212
Day's Range N/A - N/A
Shares Out 105.14M
Stochastic %K 11%
Beta 1.54
Analysts Strong Sell
Price Target $32.60

Latest News on RCUS

Arcus Biosciences Announces New Employment Inducement Grants

Mar 25, 2025, 4:35 PM EDT - 9 days ago

Arcus Biosciences Announces New Employment Inducement Grants


Arcus: Excellent Pipeline And Collaborations, Cash Runway

Jan 13, 2025, 8:00 AM EST - 2 months ago

Arcus: Excellent Pipeline And Collaborations, Cash Runway


Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 11:39 PM EST - 5 months ago

Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Transcript


Arcus Biosciences: Getting Too Cheap To Ignore (Reiterate Buy)

Aug 9, 2024, 5:31 PM EDT - 8 months ago

Arcus Biosciences: Getting Too Cheap To Ignore (Reiterate Buy)


Arcus Biosciences, Inc. (RCUS) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 5:21 PM EDT - 8 months ago

Arcus Biosciences, Inc. (RCUS) Q2 2024 Earnings Call Transcript


Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript

May 8, 2024, 9:55 PM EDT - 11 months ago

Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript


Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey

Nov 20, 2023, 2:19 PM EST - 1 year ago

Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey